These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31652113)

  • 1. Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.
    Almeida MJ; Matos A
    Curr HIV Res; 2019; 17(5):306-323. PubMed ID: 31652113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
    Allers K; Schneider T
    Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editing CCR5: a novel approach to HIV gene therapy.
    Cornu TI; Mussolino C; Bloom K; Cathomen T
    Adv Exp Med Biol; 2015; 848():117-30. PubMed ID: 25757618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
    Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E
    J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.
    Hütter G; Bodor J; Ledger S; Boyd M; Millington M; Tsie M; Symonds G
    Viruses; 2015 Jul; 7(8):4186-203. PubMed ID: 26225991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5-edited gene therapies for HIV cure: Closing the door to viral entry.
    Haworth KG; Peterson CW; Kiem HP
    Cytotherapy; 2017 Nov; 19(11):1325-1338. PubMed ID: 28751153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5.
    Mock U; Machowicz R; Hauber I; Horn S; Abramowski P; Berdien B; Hauber J; Fehse B
    Nucleic Acids Res; 2015 Jun; 43(11):5560-71. PubMed ID: 25964300
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Xu M
    Cell Biosci; 2020; 10():48. PubMed ID: 32257106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects.
    Lai Y
    Curr Stem Cell Res Ther; 2012 Jul; 7(4):310-7. PubMed ID: 22486585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
    Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
    Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
    Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
    Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Applications of Genome Editing to HIV Cure.
    Wang CX; Cannon PM
    AIDS Patient Care STDS; 2016 Dec; 30(12):539-544. PubMed ID: 27854119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout.
    Mehmetoglu-Gurbuz T; Yeh R; Garg H; Joshi A
    Virol J; 2021 Jan; 18(1):31. PubMed ID: 33516234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
    Xu L; Wang J; Liu Y; Xie L; Su B; Mou D; Wang L; Liu T; Wang X; Zhang B; Zhao L; Hu L; Ning H; Zhang Y; Deng K; Liu L; Lu X; Zhang T; Xu J; Li C; Wu H; Deng H; Chen H
    N Engl J Med; 2019 Sep; 381(13):1240-1247. PubMed ID: 31509667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
    Takácová M; Nogová P; Hábeková M; Staneková D
    Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases.
    Li L; Krymskaya L; Wang J; Henley J; Rao A; Cao LF; Tran CA; Torres-Coronado M; Gardner A; Gonzalez N; Kim K; Liu PQ; Hofer U; Lopez E; Gregory PD; Liu Q; Holmes MC; Cannon PM; Zaia JA; DiGiusto DL
    Mol Ther; 2013 Jun; 21(6):1259-69. PubMed ID: 23587921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical applications of genome editing in HIV.
    Wang CX; Cannon PM
    Blood; 2016 May; 127(21):2546-52. PubMed ID: 27053530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases.
    Rogers GL; Cannon PM
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):883-895. PubMed ID: 28895854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR5 Promoter Polymorphism -2459G > A: Forgotten or Ignored?
    Mehlotra RK
    Cells; 2019 Jun; 8(7):. PubMed ID: 31261839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.